• 보장 된 프라이버시를 가진 펩티드를 연구합니다
X
큐

멜라 노탄 2 (MT2) 10mg

주문하려면 연락
세균성 물

멜라노탄 -2(MT-2)는 알파-멜라노 사이트 자극 호르몬의 합성 유사체이다. 1980 년대에 개발 된 Melanotan-2는 성적 흥분을 증가시키고, 강박/중독성 행동을 줄이고, 기아를 억제하며 멜라닌 생산을 증가시키는 것으로 나타났습니다. 연구에 따르면 펩티드는 멜라닌 세포를 자극하여 피부 색소 침착을 증가시키고 유아기 발달 중에 사용될 때 자폐증과 싸우는 데 도움이 될 수 있습니다.

유리 (1) 30 ml 세균성 물
자격을 갖춘 주문이 있습니다$ 500 USD.
(캡슐 제품, 미용 펩티드, 프로모션 코드 및 배송 제외)

멜라노탄 -2(MT-2)는 알파-멜라노 사이트 자극 호르몬의 합성 유사체이다. 1980 년대에 개발 된 Melanotan-2는 성적 흥분을 증가시키고, 강박/중독성 행동을 줄이고, 기아를 억제하며 멜라닌 생산을 증가시키는 것으로 나타났습니다. 연구에 따르면 펩티드는 멜라닌 세포를 자극하여 피부 색소 침착을 증가시키고 유아기 발달 중에 사용될 때 자폐증과 싸우는 데 도움이 될 수 있습니다.

제품 사용 :이 제품은 연구 화학 물질로만 의도 된 것입니다.이 명칭은 시험 관내 시험 및 실험실 실험에만 연구 화학 물질을 엄격하게 사용할 수있게한다. 이 웹 사이트에서 제공되는 모든 제품 정보는 교육 목적으로 만 사용됩니다. 인간이나 동물에 어떤 종류의 신체적으로 소개되는 것은 법에 의해 엄격히 금지되어 있습니다. 이 제품은 라이센스가 부여 된 자격을 갖춘 전문가 만 처리해야합니다. 이 제품은 약물, 음식 또는 화장품이 아니며 약물, 음식 또는 화장품으로 잘못 브랜드화되거나 잘못 사용되거나 오해가되지 않을 수 있습니다.

Melanotan 2 (MT-2)는 무엇입니까?

멜라 노탄 2 (MT-2)는 인간 알파-멜라노 사이트 자극 호르몬 (α-MSH)의 합성 버전이다. 그것은 원래 1980 년대 애리조나 대학교에서 α-MSH가 설치류에서 성적 각성을 일으키고 피부의 어두워진다는 사실을 발견 한 후 개발되었습니다. 원래 태양없는 태닝 옵션으로 설계된 MT-2는 결국 다음과 같은 다양한 효과를 갖는 것으로 밝혀졌습니다.

  • 성적 흥분 증가,
  • 태닝 또는 피부 색소 침착 홍보,
  • 강박 행동 감소,
  • 중독 통제,
  • 굶주림 싸움,
  • 글루카곤 생산 감소
  • 자폐증의 특징을 역전시킵니다.

멜라 노탄 2 펩티드 구조

펩티드 서열 :nle-asp (1) -His-d-phe-arg-trp-lys (1)
분자식 :C50H69N15O9
분자량 :1024.198 g/mol
Pubchem CID : 92432
CAS 번호 :121062-08-6

멜라 노탄 2 펩티드 구조원천:Pubch

Melanotan 2 연구

멜라 노탄 2 및 멜라노 코르틴 신호 전달

멜라 노탄 2는 멜라노 코르 틴 수용체와 결합함으로써 그 효과를 생성한다. 각각 다른 기능을 갖는 5 개의 알려진 멜라노 코르틴 수용체가 있습니다. MT-2는 주로 MC-4R 및 MC-1R에 결합하는 것으로 알려져 있지만 MC-3R에도 약하게 결합한다.

  • MC-1R : 멜라노 사이트에서 발견되는 MC-1R의 자극은 피부와 모발의 어두워집니다.
  • MC-2R : 부신에서 발견 된 MC-2R 결합은 코티솔과 같은 부신 호르몬의 분비를 촉진합니다.
  • MC-3R : MC-3R은 식욕 제어 및 에너지 조절에 관여하지만,이 수용체에 대해서는 알려진 바가 거의 없습니다.
  • MC-4R : MC-4R의 자극은 수유 및 성적 행동의 변화를 유발합니다. 또한 남성 발기 기능과 에너지 항상성에 영향을 미칩니다.
  • MC-5R : MC-5R은 땀샘 및 췌장 섬 세포에서 발현된다.

멜라 노탄 2와 자폐증

MT-2에 대한 최신 연구 결과는 펩티드가 자폐증 스펙트럼 장애 (ASD)의 일반적으로 사용되는 마우스 모델에서 특정 자폐증 특징을 역전시킬 수 있음을 나타냅니다. 상태에 대한 치료는 없지만 최근의 검색에 따르면 옥시토신 요법이 ASD와 관련된 일부 행동 문제를 완화하는 데 유용 할 수 있습니다. 자폐증으로 이어지는 것으로 알려진 모체 면역 활성화의 마우스 모델을 사용하여, 연구원들은 옥시토신 방출을 자극하는 것으로 알려진 MT2가 ASD에 대응하거나 일반적인 ASD Beviors를 줄일 수 있는지 여부를 조사했습니다. 그들의 연구에 따르면 MT-2의 투여는이 특정 모델에서 자폐증과 관련된 의사 소통 감소, 사회적 상호 작용 장애 및 반복적 인 행동을 역전 시킨다는 것이 밝혀졌습니다. 실제로, 연구자들은 MT-2 투여가 뇌의 특정 부분에서 옥시토신 수용체의 발현을 증가시켜 해당 영역에서 옥시토신 신호와 ASD- 특이 적 행동 사이의 직접적인 상관 관계를 시사한다는 것을 발견했다.[1].

Impact of MT-2 on sociability in rats with ASD (MIA) showing that MT-2 returns sociability ratings to near the baseline of control animals (C57).
Source: PubMed

These findings not only suggest potential avenues for developing a treatment for ASD, they have helped to define a specific brain pathway that may be integral to the development of ASD in the first place. These findings could help scientists develop a complete model of ASD and thus both treatments and preventative measures.

Melanotan 2 and Hunger

There is good evidence to suggest that MT-2 can reduce fat storage and hunger behavior in animal models. Researchers have found that the melanocortin-4 receptor (MC-4R) plays a role in food preferences and intake and that MT-2 is a potent agonist of MC-4R. Administration of MT-2 to mice causes significant reductions in how much food they consume, but also changes their preference for fatty foods. Mice given MT-2 ignore fatty foods, which they would otherwise prefer. Similarly, mice devoid of the MC-4R receptor consume fatty foods almost exclusively and are immune to the effects of MT-2[2].

The effects of MT-2 are similar to those of the hormone leptin, sometimes called the satiety hormone because it reduces cravings and food intake. Leptin, however, has never been useful in the treatment of obesity, even in individuals who are leptin deficient. This is likely because there are two pathways for satiety, called leptin-dependent and leptin-independent pathways. Research suggests MT-2 is more effective in stimulating both pathways and thus may be a more effective exogenous treatment for reducing hunger[3], [4]. This latter finding has been bolstered by the discovery that thyrotropin-releasing hormone (TRH) gene expression, which has long been known to play a role in the leptin-satiety pathway, is also affected by MC-4R stimulation[5]. Both MT-2 and leptin are thought to cause an increase in TRH expression in the paraventricular nucleus of the hypothalamus, a region of the brain associated with satiety and food intake, but only MT-2 crosses into the central nervous system in concentrations high enough to have an effect on TRH expression.

Melanotan 2 and Diabetes

The pathogenesis of diabetes is defined by high blood sugar levels, hypersecretion of glucagon, and the production of ketone bodies[6]. It has been known for some time that leptin counteracts these factors by increasing the uptake of glucose, suppressing glucagon production, and interfering with the pathway that leads to ketone body formation. These actions do not depend on insulin and thus leptin signaling is being actively investigated as an alternative means by which diabetes might be treated.

Research has revealed that leptin’s effects on blood sugar are regulated through melanocortin receptors and that MT-2 produces similar effects[7]. This is significant because leptin has its primary effects in the brain but does not cross the blood-brain barrier as readily as MT-2. Thus, exogenously administered leptin does not reach the CNS in substantial quantities, a fact that reduces its effectiveness as a drug and hands an advantage to MT-2 even though the effects of the two peptides on melanocortin receptors are nearly identical.

Melanotan 2, Impulse Control and Alcohol Intake

In keeping with the idea that MT-2 may affect oxytocin signaling and thus behavior in ASD, research also reveals that the MC-4R receptor may play a role in impulse control. Past studies in rats have shown that administration of MT-2 reduces alcohol intake and increases water intake even in rats that prefer alcohol[8]. More recently, research has revealed that melanotan-2 works synergistically (boosting efficacy more than seven-fold) with naltrexone to blunt binge-like ethanol intake in mice[9].

Percent of baseline alcohol consumption in mice treated with naltrexone or naltrexone and MT-2.
Source: PubMed

These findings suggest that MT-2 might not only be an effective treatment in alcohol-related disorders, but that the peptide is tapping into a more fundamental process of craving and desire in the mammalian brain. This research may open up pathways to a deeper understanding not just of alcohol abuse and hunger, but the role of oxytocin in impulsive behavior. It may even help researchers identify craving pathways and advance our understanding of human motivation in aspects of life ranging from work to relationships.

Melanotan 2 and Erectile Dysfunction

Erectile dysfunction (ED) is often attributed to vascular issues and can be effectively treated in a majority of men via sildenafil (Viagra) and other drugs that improve blood flow by reducing vascular resistance. Not all ED is due to vascular issues, however, and so sildenafil and similar drugs are ineffective in a small percentage of men and in the vast majority of women who suffer from hypoactive sexual desire disorder. It has long been known that MT-2 is an effective treatment for ED, but research suggests that it may have more wide-ranging application than drugs like sildenafil due to its actions in the central nervous system. In a study of men who had failed treatment with Viagra, eighty percent responded to MT-2 treatment[10]. MT-2 has been actively investigated in the past as a treatment for both male and female sexual desire disorders.

Future MT-2 Research

MT-2 is a heavily researched peptide, particularly regarding human behavior, sexual desire, and impulse control. The peptide, in various forms, has been investigated in clinical trials, though problems with routes of administration have forced scientists back to the drawing board. There is active and ongoing research into the benefits of this particular peptide.

MT-2 exhibits minimal to moderate side effects, low oral and excellent subcutaneous bioavailability in mice. Per kg dosage in mice does not scale to humans. MT-2 for sale at

Peptide Gurus is limited to educational and scientific research only, not for human consumption. Only buy MT-2 if you are a licensed researcher.

Article Author

The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Scientific Journal Author

Dr. Wessells is a UW professor, chair of the Department of Urology, and has served on several national and international professional and government committees, including the WHO International Consultations on Erectile and Sexual Dsyfunction, an NIDDK working group on urological complications of diabetes, and a NIH symposium on diabetes. He is a surgeon, researcher and expert on urogenital trauma and erectile dysfunction. His clinical interests include reconstructive surgery of the genitourinary tract, acute injury management and complex surgery for male sexual dysfunction.  His research interests are in urogenital trauma epidemiology and management; the physiology and pathophysiology of erectile dysfunction; reconstructive surgery; crash injury mechanics; and urological complications of diabetes. A proerectile melanocortin agonist developed by Dr. Wessells and his collaborators at the University of Arizona is in clinical trials for the treatment of erectile dysfunction.

Dr. Wessells is being referenced as one of the leading scientists involved in the research and development of Melanotan 2. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between

Peptide Gurus and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr. Wessells is listed in [11] and [12] under the referenced citations.

Referenced Citations

  1. E. Minakova et al., “Melanotan-II reverses autistic features in a maternal immune activation mouse model of autism,” PLoS ONE, vol. 14, no. 1, Jan. 2019.
  2. A. van der Klaauw et al., “Role of melanocortin signalling in the preference for dietary macronutrients in human beings,” Lancet Lond. Engl., vol. 385 Suppl 1, p. S12, Feb. 2015.
  3. H. Shimizu, K. Inoue, and M. Mori, “The leptin-dependent and -independent melanocortin signaling system: regulation of feeding and energy expenditure,” J. Endocrinol., vol. 193, no. 1, pp. 1–9, Apr. 2007.
  4. C. Bjørbaek and A. N. Hollenberg, “Leptin and melanocortin signaling in the hypothalamus,” Vitam. Horm., vol. 65, pp. 281–311, 2002.
  5. F. Guo, K. Bakal, Y. Minokoshi, and A. N. Hollenberg, “Leptin Signaling Targets the Thyrotropin-Releasing Hormone Gene Promoter in Vivo,” Endocrinology, vol. 145, no. 5, pp. 2221–2227, May 2004.
  6. Y. H. Lee, M.-Y. Wang, X.-X. Yu, and R. H. Unger, “Glucagon is the key factor in the development of diabetes,” Diabetologia, vol. 59, no. 7, pp. 1372–1375, 2016.
  7. C. Toda et al., “Distinct effects of leptin and a melanocortin receptor agonist injected into medial hypothalamic nuclei on glucose uptake in peripheral tissues,” Diabetes, vol. 58, no. 12, pp. 2757–2765, Dec. 2009.
  8. D. A. York, S. Boghossian, and M. Park-York, “Melanocortin activity in the amygdala influences alcohol intake,” Pharmacol. Biochem. Behav., vol. 98, no. 1, pp. 112–119, Mar. 2011.
  9. M. Navarro, F. Carvajal, J. M. Lerma-Cabrera, I. Cubero, M. J. Picker, and T. E. Thiele, “Evidence that Melanocortin Receptor Agonist Melanotan-II Synergistically Augments the Ability of Naltrexone to Blunt Binge-Like Ethanol Intake in Male C57BL/6J Mice,” Alcohol. Clin. Exp. Res., vol. 39, no. 8, pp. 1425–1433, Aug. 2015.
  10. “Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. – PubMed – NCBI.” [Online]. Available: [Accessed: 15-May-2019]..
  11. WESSELLS, H. , HRUBY, V. J., HACKETT, J. , HAN, G. , BALSE‐SRINIVASAN, P. and VANDERAH, T. W. (2003), MT‐II Induces Penile Erection via Brain and Spinal Mechanisms. Annals of the New York Academy of Sciences, 994: 90-95.
  12. Wessells, H. (1998). Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: Doubleblind placebo controlled crossover study. Nature.com. Available at:
  13. M. T. Islam et al., “Vasopressin neurons in the paraventricular hypothalamus promote wakefulness via lateral hypothalamic orexin neurons,” Curr. Biol. CB, pp. S0960-9822(22)01121–6, Jul. 2022, doi: 10.1016/j.cub.2022.07.020.
  14. J. K. Y. Lau et al., “Melanocortin receptor activation alleviates amyloid pathology and glial reactivity in an Alzheimer’s disease transgenic mouse model,” Sci. Rep., vol. 11, no. 1, p. 4359, Feb. 2021, doi: 10.1038/s41598-021-83932-4. 

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body.  These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease.  Bodily introduction of any kind into humans or animals is strictly forbidden by law.

Request Inquery

About us

PeptideGurus is a leading supplier of American-made research peptides, offering top-quality products at competitive prices. With a focus on excellence and customer service, they ensure a secure and convenient ordering process with global shipping.

Request a Quote

Peptide Gurus
  • Peptide Gurus
  • info@peptidegurus.com
  • Glendale, AZ, USA
  • © Copyright Peptide Gurus 2024. All rights reserved.
    All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration or HEALTH CANADA. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
    PeptideGurus is a chemical supplier. PeptideGurus is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. Peptide Sciences is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.

    CONTACT

    Request Inquery